BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 8174794)

  • 1. Theoretical and technical concerns in inactivation/elimination of viruses in plasma derivatives.
    Hilfenhaus J; Niedrig M; Nowak T
    Dev Biol Stand; 1993; 81():117-23. PubMed ID: 8174794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Theoretical considerations on viral inactivation or elimination.
    Willkommen H; Löwer J
    Dev Biol Stand; 1993; 81():109-16. PubMed ID: 8174793
    [No Abstract]   [Full Text] [Related]  

  • 3. At what stage should virus inactivation be carried out?
    Dorner F; Barrett PN; Eibl J
    Dev Biol Stand; 1993; 81():137-43. PubMed ID: 8174796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Viral safety of solvent-detergent treated blood products.
    Horowitz B; Prince AM; Horowitz MS; Watklevicz C
    Dev Biol Stand; 1993; 81():147-61. PubMed ID: 8174797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Considerations in performing virus spiking experiments and process validation studies.
    Darling AJ
    Dev Biol Stand; 1993; 81():221-9. PubMed ID: 8174806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inactivation of HIV, HBV, HCV related viruses and other viruses in human plasma derivatives by pasteurisation.
    Nowak T; Niedrig M; Bernhardt D; Hilfenhaus J
    Dev Biol Stand; 1993; 81():169-76. PubMed ID: 8174799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Viral safety evaluation of plasma-derived therapeutic products.
    Farshid M
    Dev Biol (Basel); 2004; 118():11-5. PubMed ID: 15645668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viral safety of Nanogam, a new 15 nm-filtered liquid immunoglobulin product.
    Terpstra FG; Parkkinen J; Tölö H; Koenderman AH; Ter Hart HG; von Bonsdorff L; Törmä E; van Engelenburg FA
    Vox Sang; 2006 Jan; 90(1):21-32. PubMed ID: 16359352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of purification procedures for removing and/or inactivating viruses in biologicals: points to consider.
    Vicari G
    Dev Biol Stand; 1991; 75():227-32. PubMed ID: 1794625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chromatographic removal of viruses from plasma derivatives.
    Burnouf T
    Dev Biol Stand; 1993; 81():199-209. PubMed ID: 8174804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Affinity chromatography to remove viruses during preparation of plasma derivatives.
    Lawrence JE
    Dev Biol Stand; 1993; 81():191-7. PubMed ID: 8174803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of bacteriophages as surrogates for mammalian viruses.
    McAlister M; Aranha H; Larson R
    Dev Biol (Basel); 2004; 118():89-98. PubMed ID: 15645677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Viral validation of the manufacturing process of high purity albumin from placentas.
    Grandgeorge M; Véron JL
    Dev Biol Stand; 1993; 81():237-44. PubMed ID: 8174808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Criteria for the choice of viruses in validation studies.
    Minor PD
    Dev Biol Stand; 1993; 81():215-9. PubMed ID: 8174805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Validation of the virus inactivation capacity of a procedure of human plasma albumin purification by chromatography].
    Stoltz JF; Geschier C; Rivat C; Sertillanges P; Grandgeorges M; Liautaud J; Regnault V; Dumont L
    Ann Pharm Fr; 1993; 51(2):78-93. PubMed ID: 8250488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of removal of human retroviruses.
    Marcus-Sekura CJ
    Dev Biol Stand; 1991; 75():133-43. PubMed ID: 1794615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Viral safety of C1-inhibitor NF.
    Terpstra FG; Kleijn M; Koenderman AH; Over J; van Engelenburg FA; Schuitemaker H; van 't Wout AB
    Biologicals; 2007 Jun; 35(3):173-81. PubMed ID: 17071103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety issues for plasma derivatives and benefit from NAT testing.
    Willkommen H; Schmidt I; Löwer J
    Biologicals; 1999 Dec; 27(4):325-31. PubMed ID: 10686059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Viral validation design of a manufacturing process.
    Larzul D
    Dev Biol Stand; 1999; 99():139-50. PubMed ID: 10404885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogen safety of human C1 esterase inhibitor concentrate.
    Gröner A; Nowak T; Schäfer W
    Transfusion; 2012 Oct; 52(10):2104-12. PubMed ID: 22413956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.